Synergism of a Novel 1,2,4-oxadiazole-containing Derivative with Oxacillin against Methicillin-Resistant Staphylococcus aureus

Abstract

Staphylococcusaureus is an important opportunistic pathogen that causes many infections in humans and animals. The inappropriate use of antibiotics has favored the diffusion of methicillin-resistant S. aureus (MRSA), nullifying the efforts undertaken in the discovery of antimicrobial agents. Oxadiazole heterocycles represent privileged scaffolds for the development of new drugs because of their unique bioisosteric properties, easy synthesis, and therapeutic potential. A vast number of oxadiazole-containing derivatives have been discovered as potent antibacterial agents against multidrug-resistant MRSA strains. Here, we investigate the ability of a new library of oxadiazoles to contrast the growth of Gram-positive and Gram-negative strains. The strongest antimicrobial activity was obtained with compounds 3 (4 µM) and 12 (2 µM). Compound 12, selected for further evaluation, was found to be noncytotoxic on the HaCaT cell line up to 25 µM, bactericidal, and was able to improve the activity of oxacillin against the MRSA. The highest synergistic interaction was obtained with the combination values of 0.78 μM for compound 12, and 0.06 μg/mL for oxacillin. The FIC index value of 0.396 confirms the synergistic effect of compound 12 and oxacillin. MRSA treatment with compound 12 reduced the expression of genes included in the mec operon. In conclusion, 12 inhibited the growth of the MRSA and restored the activity of oxacillin, thus resulting in a promising compound in the treatment of MRSA infection.

Unveiling the modulation of Pseudomonas aeruginosa virulence and biofilm formation by selective histone deacetylase 6 inhibitors

“…The minimal inhibitory concentration (MIC) of all the compounds was determined in Mueller-Hinton medium (MH) by the broth microdilution assay, following the procedure already described (Buommino et al, 2021). The compounds were added to bacterial suspension in each well, yielding a final cell concentration of 1 × 10 6 CFU/mL and a final compound concentration ranging from 3.25 to 100 μM.…”

A Review on Five and Six-Membered Heterocyclic Compounds Targeting the Penicillin-Binding Protein 2 (PBP2A) of Methicillin-Resistant Staphylococcus aureus (MRSA)

“…In a recent report, Yadav and Ganguly et al [141,144] mention that a novel quinazolinone-based small molecule was found to have an inhibitory activity that was as effective as non-β-lactam antibiotics towards the MRSA pathogen by possibly targeting the PBP2a leading to the inhibition of the cell wall synthesis. The bioisosteric modifications of lead molecules helped in the retention of pharmacophoric features and led to novel quinazolinone derivative pyrazole and benzimidazole-based small molecules.…”

“…In drug discovery, benzimidazoles are heterocyclic ring systems that have attracted numerous researchers worldwide due to their therapeutic potential [144]. The benzimidazole nucleus is essential in lead discovery.…”

Synthesis of 1,2,4‐Oxadiazole‐sulfonamide Conjugates and Their Synergistic Effect with Ampicillin as Antimicrobial Agents

“…[9] A vast number of 1,2,4-oxadiazole-bearing molecules have been found to possess diverse biological activities, such as anticancer, anti-inflammatory, anticonvulsant, antiviral, antibacterial, and anti-Alzheimer activities, as well as specific inhibitory properties against enzymes. [10] The first in class commercial drug containing 1,2,4-oxadiazole ring Oxolamine was introduced as a cough depressant in the market. [8] Besides the enormous biological potential of oxadiazole derivatives in order to get better antibacterial motifs, we selected sulfonamide functionality.…”